Clinical Trial

Optimization of the Skin Test Procedure With Iodinated Contrast Products for Certain Patients Suspected of Immediate Hypersensitivity

Study acronym: OPT-TC-PCI
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 12, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
Hypersensitivity to iodinated contrast products (ICP) affects 1 to 3% of injected patients. These reactions require an allergological assessment with skin tests in order to distinguish allergic immunological mechanisms from other non-specific mechanisms. Current recommendations recommend carrying out prick tests followed by intradermal reactions up to a 10th dilution. However, undiluted IDRs are carried out by several teams under certain conditions, without this having been validated. Experience tends to show that these IDRs are relevant in certain patients to make the diagnosis without risk.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06498219
Lead Sponsor University Hospital, Strasbourg, France
Conditions Contrast Sensitivity
Enrollment 100 participants
Start Date 2023-12-21
Primary Completion 2024-12 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-12